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Abstract 
Due to its favorable relaxometric properties, Mn2+ is an appealing metal ion for 
magnetic resonance imaging (MRI) contrast agents. This paper reports the synthesis and 
characterization of three new triazadicarboxylate-type ligands and their Mn2+ chelates 
(NODAHep, 1,4,7-triazacyclononane-1,4-diacetate-7-heptanil; NODABA, 1,4,7-
triazacyclononane-1,4-diacetate-7-benzoic acid; and NODAHA (1,4,7-
triazacyclononane-1,4-diacetate-7-hexanoic acid). The protonation constants of the 
ligands and the stability constants of the chelates formed with Mn2+ and the endogenous 
Zn2+ ion have been determined by potentiometry. In overall, the thermodynamic 
stability of the chelates is lower than that of the corresponding NOTA analogues 
(NOTA = 1,4,7-triazacyclononane-1,4,7-triacetate), consistent with the decreased 
number of coordinating carboxylate groups. Variable temperature 1H NMRD and 17O 
NMR measurements have been performed on the paramagnetic chelates to provide 
information on the water exchange rates and the rotational dynamics. The values of the 
17O chemical shifts are consistent with the presence of one water molecule in the first 
coordination sphere of Mn2+. The three complexes are in the slow to intermediate 
regime for the water exchange rate, and they all display relatively high rotational 
correlation times, which explain the relaxivity values between 4.7 and 5.8 mM-1.s-1 (20 
MHz and 298 K). These relaxivities are higher than expected for Mn2+ chelates of such 
size and comparable to those of small monohydrated Gd3+ complexes. The amphiphilic 
[Mn(NODAHep)] forms micelles above 22 mM (its critical micellar concentration was 
determined by relaxometry and fluorescence), and interacts with HSA via its alkylic 
carbon chain providing a 60% relaxivity increase at 20 MHz due to a longer tumbling 
time.  
 
Introduction 
Magnetic Resonance Imaging (MRI) has become one of the most successful diagnostic 
imaging modalities of the last decades. A large number of MRI scans is based on the 
use of paramagnetic contrast agents (CAs) which enhance the contrast of images of 
organs and tissues. Paramagnetic metal ions such as Gd3+ and Mn2+ are adequate for the 
preparation of CAs due to their high magnetic moment, long electronic relaxation times 
and the lability of their coordinated water molecules. MRI contrast agents act by 
increasing both longitudinal (1/T1) and transverse (1/T2) relaxation rates of water 
protons in the human body, and their efficiency is expressed by their water proton 
relaxivity, ri (i = 1,2) 1. 
Thanks to its seven unpaired electrons and long electronic relaxation time, Gd3+ is the 
most widely used paramagnetic metal ion in MRI. To prevent toxicity, Gd3+ has to be 
administered to the patient in the form of a thermodynamically and kinetically stable 
chelate. Several gadolinium-based chelates have been approved as CAs, including 
Magnevist® ([Gd(DTPA)]-, DTPA = diethylenetriaminepentaacetate) 2 or Dotarem® 
([Gd(DOTA)]-, DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate) 3. 
Despite its favorable features (five unpaired d electrons, long electronic relaxation times 
and labile coordinated water molecule(s)), Mn2+ received less attention and there has 
been only one approved Mn2+-based contrast agent (Teslascan®, [MnDPDP]4-, DPDP6- 
= N,N’-dipyridoxylethylenediamine-N,N’-diacetate-5,5’-bis-(phosphate), Scheme 1) 4, 5. 
A renewed interest in Mn2+-based MRI CAs has led to a systematic development and 
study of Mn2+ chelates 6. These include linear polyaminocarboxylates like EDTA 7, 8 
(EDTA = ethylenediamine tetraacetic acid) and its derivatives such as EDTA-BOM1,2 9 
and diphEDTA 10 (bearing one or two BOM = benzyloxymethyl or a diph = 
diphenylcyclohexylphosphate substituent(s), respectively), or derivatives of DTPA 10-13 
(DTPA = diethylenetriamine pentaacetic acid). In these EDTA-type complexes, the 
Mn2+ ion has a coordination number CN of 7 with one inner sphere coordinated water 
molecule. Chelates of Mn2+ with macrocyclic polyamino-polycarboxylate ligands which 
have been described include derivatives of triazacyclononane (NOTA 14 (NOTA = 
1,4,7-triazacyclononane-1,4,7-triacetic acid) and the dimeric ENOTA 15), of diaza-
oxacyclononane (9-aneN2O derivatives 16), of tetraazacyclononane (DOTA 14) and its 
derivatives bearing four or less pendant arms 9, 17, 18, such as DOTAM (DOTAM = 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetamide), (DO3A(BOM)3 (DO3A = 
1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid, BOM = benzyloxymethyl) and 
DO2A = 1,4,7,10-tetraazacyclododecan-1,7-diacetic acid), and a 1,4-diazepine-based 
ligand (AAZTA = 6-amino-6-methylperhydro-1,4-diazepine triacetic acid) 19. The Mn2+ 
complexes of these ligands have a maximum of one water molecule on the first 
coordination sphere, and the DOTA, DOTAM and DO3A(BOM)3 complexes have no 
inner-sphere water. Bishydrated Mn2+ complexes have been reported with ligands based 
on 15- or larger membered aza- or aza-oxa crown ethers containing five donor atoms, of 
which one could be in a pyridine moiety (py), e.g. 15-aneN5 20, Me2-15-pydieneN5 21, 
15-pyN5 or 15-pyN3O2 22.  
In the development of novel and better MRI contrast agents, two main goals are 
commonly considered: higher relaxivity and specificity for organs or tissues. Human 
serum albumin (HSA), the most abundant blood serum protein, presenting high affinity 
for long carbon chain molecules, 23 is an interesting biological target for CAs, especially 
those aimed at acting as blood pool agents. Chelates bearing hydrophobic moieties can 
bind to HSA, thus increasing their blood retention time and, simultaneously, increasing 
their relaxivity due to longer tumbling times 9, 24-26. 
Several strategies have been suggested for the delivery of drugs, among them self-
aggregating molecules that can form micelles 27-29. This delivery route is known to be 
promoted by macrophage-rich tissues such as liver and spleen 30. Micellization of 
amphiphilic paramagnetic chelates has the additional advantage of increasing the 
relaxivity thanks to an increase in the tumbling time of the chelate in solution 31-36. 
Another strategy for the development of CAs targeted for specific tissues and organs 
consists in their coupling to biologically relevant molecules (monoclonal antibodies, 
peptides, peptide mimetics or non-peptidic substrates and carbohydrates 37-42) that are 
recognized by specific receptors. 
In this paper, we report the synthesis of three new triazapolycarboxylate-based ligands 
for Mn2+, NODAHep (1,4,7-triazacyclononane-1,4-diacetate-7-heptanil), NODABA 
(1,4,7-triazacyclononane-1,4-diacetate-7-benzoic acid), and NODAHA (1,4,7-
triazacyclononane-1,4-diacetate-7-hexanoic acid) (Scheme 1) and the solution 
characterization of the stability and relaxometric properties of their Mn2+ complexes 
using potentiometric and relaxometric NMR techniques. Being pentadentate, these 
ligands maintain a coordination site of the metal ion available for one water molecule. 
NODAHep has a lipophilic side chain which was introduced to endow its chelates with 
the capability of forming micelles in solution and, additionally, to interact non-
covalently with blood serum proteins, in particular HSA. NODABA and NODAHA 
were designed to act as bifunctional ligands which can be conjugated to targeting 
molecules. 
 
Results and discussion 
Synthesis 
The synthetic strategy used for the preparation of NODAHep, NODABA and 
NODAHA involved the alkylation of 1,4,7-triazacyclononane-1,4-diacetic acid tert-
butyl ester (NO2AtBu) followed by removal of the protecting groups (Scheme 2). In the 
case of NODAHep, 1-bromoheptane was reacted with NO2AtBu in the presence of 
potassium carbonate to give NODA(tBu)Hep. This compound was then treated with 
trifluoroacetic acid (TFA) to give NODAHep in a 78% yield. The synthesis of 
NODABA and NODAHA was carried out using as alkylating agents the 9-
fluorenylmethyl ester of 4-(bromomethyl)benzoic acid and the methyl ester of 6-
bromohexanoic acid to give NODA(tBu)BA and NODA(tBu)HA(me) in high yields. 
The NODABA and NODAHA were obtained by treating NODA(tBu)BA with 
trifluoracetic acid and NODA(tBu)HA(me) with a solution of NaOH. The unprotected 
carboxylic acid present in NODABA and NODAHA can be used to link a vectorizing 
moiety. 
The preparation of the Mn(II) chelates was done in HEPES buffer pH 7.4. The 
formation of the chelates occurred rapidly. 
Determination of the critical micelle concentration  
The critical micelle concentration (cmc) of [Mn(NODAHep)] was determined by two 
methods. In the first method a fluorescence probe was used, which was 8-anilino-1-
naphtalene sulfonic acid (ANS), as its luminescence is sensitive to the medium polarity. 
In polar environments, such as in water, ANS is essentially non fluorescent and in non-
polar environments, such as the inner part of micelles, it is highly fluorescent 43-45. In 
order to evaluate the micelles formation, the fluorescence intensity of ANS was 
measured at 480 nm in the presence of different chelate concentrations. As the micelles 
are forming, ANS is entrapped in the micellar compartment and an increase of its 
fluorescence can be detected 44, 45. A cmc value of 22.3 mM was determined by linear 
least-square fitting of the fluorescence emission at 480 nm versus the concentration of 
the [Mn(NODAHep)] chelate (Figure 1). The alternative method consisted in the 
measurement of the longitudinal relaxation rate of the water hydrogen nuclei with 
increasing concentrations of [Mn(NODAHep)], at 40 MHz and 298 K. Indeed, at 
concentrations below the cmc, no micelles are formed, and therefore the proton 
relaxation rate measured in the solution is only due to the free, non-aggregated 
paramagnetic complex and can be expressed as follows: 
 
ܴଵ = ݎଵ௡௔ܥெ௡           (1) 
    
where R1 is the paramagnetic relaxation enhancement, nar1  is the relaxivity of the non-
aggregated Mn2+ complex, and CMn is the Mn2+ concentration. Above the cmc, the 
measured relaxation rate is the sum of two contributions, one from the non-aggregated 
complex present at a concentration equal to the cmc, and one of the complex in the 
micellar form. The paramagnetic relaxation enhancement in this case is given by: 
 
ܴଵ = ݎଵ௡௔ × ܿ݉ܿ + ݎଵ௔(ܥெ௡ − ܿ݉ܿ) = (ݎଵ௡௔ − ݎଵ௔)ܿ݉ܿ + ݎଵ௔ܥெ௡           (2) 
 
where ar1 is the relaxivity of the aggregated form of the complex.  
The cmc is then determined from the plot of R1 as a function of CMn, and by a 
simultaneous least-squares fit of the two straight lines. The intercept of those two lines 
gives the value of the cmc, 22.8 mM in this case (Figure S1), very much consistent with 
the result obtained in the previous method. It should be noted that the relaxivity of the 
non-aggregated form is found to be 4.51 mM-1.s-1 in accordance with the 1H NMRD 
measurements (vide infra), and the relaxivity of the micellar form is found to be 9.57 
mM-1.s-1. This higher value of relaxivity was predictable, as in the micellar form the 
rotational correlation time is expected to be bigger than in the monomeric form.  
The cmc values obtained for [Mn(NODAHep)] are higher than those found for 
complexes such as [Ga(NOTAC8)] and [Al(NOTAC8)], 0.36 mM and 0.25 mM 
respectively (NOTAC8 = 1,4,7-triazacyclononane-1,4-diacetic acid-7-octanoic acid 
(Scheme 1) 46. This is somewhat surprising, considering that NODAHep and NOTAC8 
have the same length of alkyl chain, and the three complexes have no charge. Given the 
high value of cmc obtained for this complex, we will study only the monomeric form of 
the complex in the followings. 
Determination of protonation and stability constants 
The protonation constants, logKHi, of the three ligands NODAHep, NODAHA and 
NODABA, as defined in equation (3), were determined by pH-potentiometric titrations 
at I = 0.1 M KCl and 298 K.  
 
ܭு೔ = [ܪ௜ܮ][ܪ௜ିଵܮ][ܪା]           (3) 
 
Three protonation constants could be determined for NODAHep, four for NODAHA 
and five for NODABA. The titration curves are presented in Figures 2 and S2, S3 (ESI) 
and the calculated protonation constants are shown in Table 1. 
The potentiometric determination of protonation constants above pH 11 is difficult, and 
they can be assessed by 1H NMR spectroscopy if the chemical shifts of the non-labile 
protons of the ligand exhibit a chemical shift change upon deprotonation. However in 
our case, attempts to determine these protonation constants by NMR were unsuccessful 
as the chemical shift changes observed were of the same order of magnitude as the line 
broadening of the observed peaks. For this reason the values obtained from 
potentiometric titrations, with a large error taking into account the difficulty of their 
determination, have been considered. 
The protonation sequence has been previously determined for various cyclic polyaza 
polycarboxylate ligands, and it has been shown that the first two protonations of the 
ligand NOTA occur on the ring nitrogen atoms, while the third protonation occur on a 
carboxylate oxygen atom 47. So for all the ligands, we attribute the first two protonation 
constants to two nitrogen atoms of the macrocycle, and the other protonation constants 
are attributed to carboxylate functions. NODAHep is very similar to “half” ENOTA 
(Scheme 1), which displays two macrocyclic units. And indeed, the protonation 
constants of NODAHep are very close to those obtained for ENOTA (12.5, 12.2, 5.97, 
5.18, 2.73, 1.86) 15. For NODAHA, the third protonation constant can be attributed to 
the carboxylate function on the alkyl chain, as the value is close to the one of an isolated 
carboxylate function. For NODABA, the second protonation on the nitrogen is lower 
than the one of the other ligand, which can be explained by the electron withdrawing 
effect of the benzene ring. The third protonation constant can be attributed to the 
benzoate function, as the pKa of the benzoic acid substituted in the para position by a 
methyl is 4.37 48. 
Complex stability constants, logKML, complex protonation constants, logKMLH, and 
hydroxo-complexes formation (eqs (4), (5), and (6)), have been determined for 
complexes formed with Mn2+ and Zn2+ ions by direct potentiometric titrations, as the 
formation of the complexes was fast. 
 
ܭெ௅ = [ܯܮ][ܯ][ܮ]          (4) 
 
ܭெ௅ு = [ܯܮܪ][ܪ][ܯܮ]          (5) 
 
ܭெ௅(ைு) = [ܯܮ][ܯܮ(ܱܪ)][ܪ]           (6) 
 
The titration curves obtained at 1:1 metal-to-ligand ratio are presented in Figures 2 and 
S2, S3 (ESI). The stability constants obtained from the fitting of the experimental 
curves for the different complexes are summarized in Table 2. 
The formation of a monoprotonated complex and a hydroxocomplex has to be taken 
into account for NODAHA. The stability constants obtained for the Mn2+ complexes 
are similar for the three ligands and they are 5 to 6 orders of magnitude lower than the 
one obtained with Zn2+. In order to compare the thermodynamic stability of these 
complexes with those from the literature, we calculated the pMn values for conditions 
commonly used for Gd3+ chelates (pH = 7.4, [Mn2+] = 10-6 M, [L] = 10-5 M). The values 
are similar for the three complexes, and they are also similar to the one found for the 
binuclear ENOTA complex (pM = 7.7) 15. They are also in the same order of magnitude 
as the one found for pyridine-containing macrocyclic ligands with carboxylate, or 
phosphate as pendants arms 22, 50, or the ones of 9-aneN2O 16 ligands with similar 
pendant arms. They however remain 4 to 5 orders of magnitude lower than those of 
MnNOTA, or MnEDTA, and 7 orders of magnitude lower than the pMn of DOTA 51.  
17O NMR and NMRD measurements 
In order to determine the microscopic parameters that rule the relaxivity of the 
complexes, their 1H NMRD profiles have been measured. These profiles represent the 
magnetic field dependence of relaxivity on the proton Larmor precession frequency and 
can be fitted by the Solomon-Bloembergen-Morgan (SBM) theory. As a large number 
of microscopic parameters influence the 1H NMRD profiles, some of them need to be 
determined by independent techniques such as 17O NMR. The variable-temperature 17O 
transverse relaxation rates (1/T2) give access to the exchange rate of the Mn2+-
coordinated water molecule, kex; the longitudinal relaxation rates (1/T1) provide 
information about the rotational motion of the complex, and hence R, and finally the 
17O chemical shifts () inform about the hydration number (q) of the complex.  
The transverse 17O relaxation times were measured as a function of temperature on 
aqueous solutions of the three complexes. The longitudinal relaxation times were also 
measured but were not included in the fittings as the difference between the 
paramagnetic solution and the diamagnetic reference were too small to yield reliable 
values. The chemical shifts were also measured but the differences in the chemical 
shifts were too small compared to the line broadening of the peak to be included in the 
treatment of the data.  
The 17O transverse relaxation rates and the 1H NMRD data at 298, 310, and 323 K 
(Figures 3 and S4, S5) were analysed simultaneously with the SBM theory to yield the 
microscopic parameters of the complexes characterizing water exchange and rotation 
(see ESI for equations). As can be seen in the figures, the 17O reduced transverse 
relaxation rates (1/T2r) first increase and then slightly decrease with increasing 
temperature, indicating that the complexes are mainly in the slow to intermediate 
exchange regime. In the slow kinetic region, 1/T2r is directly determined by the 
exchange rate kex. At higher temperature, 1/T2r is defined by the transverse relaxation 
rate of the bound water oxygen, 1/T2m , which in turn is influenced by the water 
exchange rate, kex, the longitudinal electronic relaxation rate, 1/T1e, and the scalar 
coupling constant, A/ћ. The transverse 17O relaxation is governed by the scalar 
relaxation mechanism and thus contains no information on the rotational motion of the 
system. If we are not interested in detailed information about the electron spin 
relaxation and if we restrict the analysis of the NMRD data to medium and high 
magnetic fields, the SBM approach gives reliable information on dynamic processes 
like water exchange and rotational correlation times for small complexes 52. Therefore 
only relaxivity values above 6 MHz have been included in the simultaneous fit and the 
following parameters have been thus adjusted: the water exchange rate, kex298, the 
activation enthalpy for water exchange, H≠, the scalar coupling constant, A/ћ, the 
rotational correlation time, R298, and its activation energy, ER, and the parameters 
describing electron spin relaxation, the mean square of the zero field splitting,2, the 
correlation time for the modulation of the zero field splitting, V298, while its activation 
energy, EV, has been fixed to 20 kJ/mol. The diffusion coefficient DGdH298, and its 
activation energy EDGdH were fixed to 2310-10 m2s-1 and 20 kJmol-1, respectively. The 
distances between the Mn2+ ion and the inner and the outer sphere water protons were 
fixed to rMnH = 2.75 Å and aMnH = 3.2 Å, respectively. The parameters resulting from the 
best fit are presented in Table 3. As [Mn(NODABA)] is clearly in the slow exchange 
region, no information on the electronic parameters of these complexes can be obtained 
from the 17O T2 values. Therefore, for the analysis of this system, we decided to fix the 
electronic parameters to the values obtained from the fittings of the two other 
complexes. 
The exchange rate of the complexes are of the same order of magnitude as that of the 
aqua ion and slightly lower than the one of the dinuclear complex ENOTA. The 
negative values of the activation entropy tend to point to an associative mechanism for 
the exchange rate of the water molecule, as demonstrated for the Mn2ENOTA. The six-
coordinated monohydrated complexes will undergo an associative exchange which 
proceeds via a seven-coordinate transition state. [Mn(NODAHep)] and 
[Mn(NODABA)] are certainly six-coordinated species with one water molecule in the 
first coordination sphere of Mn2+. In the case of [Mn(NODAHA)], the carboxylate 
function on the alkyl chain could also participate in the coordination sphere of Mn2+. 
Given the species found from potentiometric measurements (presence of a protonated 
complex) and the results obtained from the activation entropy, we can conclude that the 
carboxylate function on the alkyl chain of NODAHA does not participate in the 
coordination sphere of the metal ion. The slower water exchange observed for 
[Mn(NODABA)] can be explained by the presence of the bulky benzyl ring, which 
does not facilitate the approach of the second water molecule in the water exchange 
mechanism. The scalar coupling constants found are typical of a Mn2+ complex 16, 22, 
confirming the monohydrated character of the complex. 
The 1H NMRD profiles are comparable to those of Mn(EDTA) and other monohydrated 
Mn2+ complexes. No second dispersion is observed at low field, unlike what has been 
observed for the dinuclear Mn2ENOTA complex. This absence of second dispersion 
moreover confirms the absence of free Mn2+. The relaxivities of [Mn(NODAHep)], 
[Mn(NODAHA)] and [Mn(NODABA)] at 20 MHz and 298 K are respectively 4.73, 
4.58 and 5.47 mM-1.s-1, remarkably higher than that of the similarly monohydrated 
Mn(EDTA) (3.0 at 24 MHz, 298 K) 54. This difference can be accounted for by the 
larger size of our complexes. The slightly higher value observed for [Mn(NODABA)] 
can be explained by the higher rotational correlation time of the complex. 
These relaxivities are similar to those of Gd3+ chelates with one water molecule in the 
first coordination sphere of the metal ion (GdDOTA: r1 = 4.2 mM-1.s-1; GdDTPA: r1 = 
4.3 mM-1.s-1) 41. In general, considering chelates of similar size, Gd3+ complexes have 
higher relaxivities because of the higher electron spin of Gd3+ with respect to Mn2+. A 
general feature of Mn2+ complexes with respect to the Gd3+ analogues is their faster 
water exchange which can be advantageous to attain high relaxivities, but only for 
slowly rotating systems.  
We have also measured the NMRD profile of [Mn(NODAHep)] in the presence of 
HSA (Figure S6 in ESI). Given the hydrophobic nature of the alkyl chain, non-covalent 
binding between the complex and the protein through hydrophobic interactions is 
expected as it was reported for various Gd3+- 55 and some Mn2+-chelates 9, 10. Indeed, the 
NMRD curve displays a “hump” between 10 and 80 MHz, typical of slowly rotating 
complexes (at 20 MHz, the relaxivity is nearly doubled in the presence of HSA) 
confirming that the complex is bound to HSA through hydrophobic interaction. We 
should note that this interaction is certainly not specific to HSA, but would be operative 
for many other proteins as well.  
pH stability 
The stability of [Mn(NODAHep)] was also investigated as a function of the pH. The 
increase of relaxivity observed upon going from basic to acidic pH can be attributed to 
the decomplexation of Mn2+ ion at acidic pH, lower than 5. This is indeed in accordance 
with the species distribution obtained from the stability constant of [Mn(NODAHep)] 
determined by potentiometry (Figure 4). We can conclude that in the pH range 7.4 - 9.3, 
the complex is formed. 
 
Conclusions 
In this paper we introduce three new chelators designed for Mn2+ as potential MRI CAs. 
The protonation constants and the thermodynamic stabilities of their Mn2+ and Zn2+ 
chelates have been determined by pH potentiometry. The thermodynamic stability 
constants are lower in comparison to those of the analogous NOTA chelates. The 
parameters governing relaxivity have been obtained by 1H NMRD and 17O NMR 
studies. They are compatible with small molecular weight chelates displaying one inner 
sphere water molecule that exchanges via an associative water exchange mechanism. 
The Mn2+ chelates display relaxivities between 4.6 and 5.5 mM-1.s-1 (20 MHz and 298 
K), values which are similar to those of monohydrated Gd3+ chelates. The slightly 
higher relaxivity value found for [Mn(NODABA)] is explained by a longer rotational 
correlation time. 
The alkylic pendant chain of NODAHep endows its Mn2+ chelate with amphiphilic 
character, forming micelles in solution. Its cmc has been determined by two distinct 
methods, affording similar values (22.3 mM by fluorescence and 22.8 mM by 
relaxivity). Simultaneously the alkylic chain permits the chelate to interact with HSA, 
resulting in a 60% relaxivity increase (at concentrations similar to those present in the 
blood, 4% (0.6 mM) 56) due to an even longer tumbling time. It is also expected that the 
interaction with HSA might increase the retention time of the chelate in the blood 
stream. 
 
Experimental 
Materials and methods 
Analytical grade reagents were purchased from Sigma-Aldrich, Fluka, Acros Organics, 
Macrocyclics and Chematech. The reactions were monitored by thin layer 
chromatography (TLC) on aluminum plates coated with silica gel 60 F254 (Macherey-
Nagel). Chromatography separations were performed on silica gel Whatman 230-240 
Mesh. The NMR spectra were recorded on a Varian Unity Plus 300 spectrometer or on 
a BrukerAvance III 400 spectrometer. The 1H NMR spectra were assigned using the 
two-dimensional COSY technique. The 1H chemical shifts are reported in ppm, relative 
to tetramethylsilane (TMS) or sodium 2,2-dimethylsilapentane-5-sulfonate (DSS) and 
the following abbreviations are used: s = singlet; d = duplet; t = triplet; m = multiplet. 
pH measurements were performed on a pH meter Crison micro TT 2050 with an 
electrode Mettler Toledo InLab 422. Mass spectra (ESI+) were performed on a VG 
Autospec M spectrometer or on a Finnigan LXQ MS Detector.  
Synthetic procedures 
NODA(tBu)Hep 
To a solution of NO2AtBu (0.520 g, 1.45 mmol) in acetonitrile (22 mL), K2CO3 (0.606 
g, 4.38 mmol) and 1-bromoheptane (0.230 mL, 1.46 mmol) were added. The reaction 
was stirred for 96 h. The reaction mixture was filtered and the solvent removed under 
reduced pressure. The oil obtained was purified by column chromatography using 
dichloromethane/ethanol 7:3 and dichloromethane/ethanol/NH3 7:3:0.5. The 
NODA(tBu)Hep (0.660 g, 1.45 mmol) was obtained as an oil with 100% yield. H (300 
MHz; CDCl3; TMS) 0.85 (3 H, t, J = 6.8 Hz, (CH2)6CH3), 1.24 (8 H, m, (CH2)6CH3), 
1.43 (20 H, m, (CH2)6CH3 and C(CH3)3), 2.48 (2 H, t, J = 7.8 Hz, (CH2)6CH3), 2.70-
2.90 (12 H, m, en) and 3.29 (4 H, s, CH2CO2tBu). C (100.61 MHz; CDCl3; TMS) 14.02 
((CH2)6CH3), 22.56 ((CH2)6CH3), 27.42 ((CH2)6CH3), 28.16 (C(CH3)3), 29.18 
((CH2)6CH3), 31.79 ((CH2)6CH3), 55.20 (en), 58.61 ((CH2)6CH3), 59.73 (CH2CO2tBu), 
80.65 (C(CH3)3) and 171.46 (CH2CO2tBu). HRMS (ESI+) calculated for C25H50N3O4 
(M+H)+ 456.38013. Found 456.37890. 
NODAHep 
Trifluoracetic acid (30 mL) was added to a solution of NODA(tBu)Hep (0.660 g, 1.45 
mmol) in dichloromethane (30 mL). The mixture was left stirring at room temperature 
overnight. The solvent was removed under reduced pressure and the oil obtained was 
washed with hexane (3 x 15 mL) and water (3 x 15 mL). The NODAHep (0.775 g, 1.13 
mmol) was obtained as an oil with 78% yield. H (300 MHz; D2O; DSS) 0.84 (3 H, t, J 
= 6.8 Hz, (CH2)6CH3), 1.20-1.40 (8 H, m, (CH2)6CH3), 1.72-1.82 (2 H, m, (CH2)6CH3), 
3.28-3.65 (14 H, m, (CH2)6CH3 and en) and 3.86 (4 H, s, CH2CO2H). C (75.43 MHz; 
D2O; DSS) 13.46 ((CH2)6CH3), 22.00 ((CH2)6CH3), 23.80 ((CH2)6CH3), 25.78 
((CH2)6CH3), 27.98 ((CH2)6CH3), 30.92 ((CH2)6CH3), 49.57 (en), 50.68 (en), 50.92 (en), 
57.06 (CH2CO2H), 58.29 ((CH2)6CH3) and 173.29 (CH2CO2H). HRMS (ESI+) 
calculated for C17H34N3O4 (M+H)+ 344.25493. Found 344.25378. 
9-Fluorenylmethyl 4-(bromomethyl)benzoate 
N,N′-dicyclohexylcarbodiimide (0.484 g, 2.34 mmol) and 4-(dimethylamino)pyridine 
(0.015 g, 0.123 mmol) were added to a solution of 4-(bromomethyl)benzoic acid (0.505 
g, 2.35 mmol) and 9-fluorenemethanol (0.508 g, 2.59 mmol) in dry dichloromethane (15 
mL) in ice bath. The reaction was stirred, at room temperature, for 72 h. The reaction 
mixture was filtered and the solvent removed under reduced pressure. The residue 
obtained was purified by column chromatography eluted using cyclohexane/ethyl 
acetate 4:1. The 9-fluorenylmethyl 4-(bromomethyl)benzoate (0.436 g, 1.15 mmol) 
was obtained as an oil with 49% yield. H (400 MHz; CDCl3; TMS) 4.40 (1 H, t, J = 7.2 
Hz, Fm), 4.53 (2 H, s, C6H4CH2Br), 4.64 (2 H, d, J = 7.2 Hz, Fm), 7.34 (2 H, t, J = 7.6 
Hz, Fm), 7.44 (2 H, t, J = 7.4 Hz, Fm), 7.52 (2 H, d, J = 7.8 Hz, C6H4CH2Br), 7.66 (2 H, 
t, J = 7.6 Hz, Fm), 7.81 (2 H, t, J = 7.6 Hz, Fm) and 8.07 (2 H, d, J = 7.8 Hz, 
C6H4CO2Fm). C (100.61 MHz; CDCl3; TMS) 32.15 (PhCH2Br), 46.91 (CH2CH Fm), 
67.12 (CH2CH Fm), 120.08 (Fm), 125.02 (Fm), 127.17 (Fm), 127.85 (Fm), 129.18 
(C6H4CH2Br), 130.01 (C6H4CH2Br), 130.11 (C6H4CH2Br), 141.34 (Fm), 142.82 
(C6H4CH2Br), 143.73 (Fm) and 165.90 (PhCO2Fm). 
NODA(tBu)BA 
To a solution of NO2AtBu (0.301 g, 0.842 mmol) in acetonitrile (20 mL), K2CO3 (0.472 
g, 3.42 mmol) and 9-fluorenylmethyl 4-(bromomethyl)benzoate (0.318 g, 0.838 mmol) 
were added. The reaction was stirred for several days. The reaction mixture was filtered 
and the solvent removed under reduced pressure. The oil obtained was purified by 
column chromatography eluted using ethyl acetate/ethanol 1:1, ethanol and ethanol/NH3 
10:0.5. NODA(tBu)BA (0.410 g, 0.834 mmol) was obtained as an oil in 99% yield. H 
(300 MHz; CDCl3; TMS) 1.42 (18 H, s, C(CH3)3), 2.79-3.47 (16 H, m, en and 
CH2CO2tBu), 4.23 (2 H, s, CH2C6H4CO2H), 7.50 (2 H, d, J = 7.8 Hz, CH2C6H4CO2H) 
and 8.02 (4 H, d, J = 8.1 Hz, CH2 C6H4CO2H). C (75.43 MHz; CDCl3; TMS) 28.10 
(C(CH3)3), 51.68 (en), 52.43 (en), 55.00 (en), 59.47 (CH2C6H4CO2H and CH2CO2tBu), 
81.24 (C(CH3)3), 129.74 (CH2C6H4CO2H), 129.93 (CH2C6H4CO2H), 135.52 
(CH2C6H4CO2H), 136.55 (CH2C6H4CO2H), 170.73 (CH2CO2tBu) and 171.11 
(CH2C6H4CO2H). HRMS (ESI+) calculated for C26H42N3O6 (M+H)+ 492.30736. Found 
492.30612. 
NODABA 
Trifluoracetic acid (18 mL) was added to a solution of NODA(tBu)BA (0.415 g, 0.844 
mmol) in dichloromethane (18 mL). The mixture was left stirring overnight and solvent 
removed under reduced pressure. The oil obtained was washed with hexane (3 x 9 mL) 
and water (3 x 9 mL). NODABA (0.470 g, 0.651 mmol) was obtained in 77% yield, as 
an oil. H (400 MHz; D2O; DSS) 3.25-3.63 (12 H, m, en), 3.81 (4 H, s, CH2CO2H), 4.57 
(2 H, s, CH2C6H4CO2H), 7.67 (2 H, d, J = 6.3 Hz, CH2C6H4CO2H) and 8.06 (2 H, d, J = 
6.3 Hz, CH2C6H4CO2H). C (100.6 MHz; D2O; DSS) 49.36 (en), 50.31 (en), 50.74 (en), 
56.32 (CH2CO2H), 60.37 (CH2C6H4CO2H), 130.50 (CH2C6H4CO2H), 131.28 
(CH2C6H4CO2H), 131.44 (CH2C6H4CO2H), 134.13 (CH2C6H4CO2H), 169.53 
(CH2C6H4CO2H) and 172.56 (CH2CO2H). HRMS (ESI+) calculated for C18H26N3O6 
(M+H)+ 380.18216. Found 380.18152. 
Methyl 6-bromohexanoate 
Thionyl chloride (3.74 mL, 51.3 mmol) was slowly added to methanol (15 mL) in an ice 
bath. A solution of 6-bromohexanoic acid (2.002 g, 10.26 mmol) in 30 mL of methanol 
was added to the previous solution. The mixture was left stirring at 313 K for 4 h. The 
solvent was evaporated giving methyl 6-bromohexanoate (1.903 g, 9.10 mmol) in 
89% yield as a solid. H (300 MHz; CDCl3; TMS) 1.46 (2 H, m, CH2), 1.65 (2 H, m, 
CH2), 1.86 (2 H, m, CH2), 2.32 (2 H, t, J = 7.5 Hz, CH2), 3.39 (2 H, t, J = 6.6 Hz, 
CH2) and 3.66 (3 H, s, CH3).  
NODA(tBu)HA(me) 
K2CO3 (0.241 g, 1.741 mmol) and methyl 6-bromohexanoate (0.148 g, 0.707 mmol) 
were added to a solution of NO2AtBu (0.211 g, 0.589 mmol) in acetonitrile (15 mL). 
The reaction was stirred for 96 h. The reaction mixture was filtered and the solvent 
removed under reduced pressure. The oil obtained was purified by column 
chromatography eluted using dichloromethane/ethanol 7:3 and 
dichloromethane/ethanol/NH3 7:3:0.5. The NODA(tBu)HA(me) (0.282 g, 0.581 mmol) 
was obtained with 99% yield, as an oil. H (300 MHz; CDCl3; TMS) 1.31 (2 H, m, 
CH2), 1.36 (18 H, s, C(CH3)3), 1.57 (4 H, m, CH2 and CH2), 2.25 (2 H, t, J = 7.2 Hz, 
CH2), 2.62-3.10 (14 H, m, CH2 and en), 3.28 (4 H, s, CH2CO2tBu) and 3.60 (3 H, s, 
CH3). C (75.43 MHz; CDCl3; TMS) 24.56 (CH2), 26.02 (CH2), 26.66 (CH2), 28.10 
(C(CH3)3), 33.80 (CH2), 51.40 (CH3), 53.98 (en), 54.83 (en), 57.33 (CH2), 59.27 
(CH2CO2 tBu), 80.83 (C(CH3)3), 171.60 (CH2CO2 tBu) and 173.92 (CO2CH3). HRMS 
(ESI+) calculated for C25H48N3O6 (M+H)+ 486.35431. Found 486.35278. 
NODAHA 
A solution of NaOH 1M (7.5 mL) was added to a solution of NODA(tBu)HA(me) 
(0.225 g, 0.483 mmol) in methanol (2.5 mL). The reaction was left at reflux overnight. 
The mixture was neutralized with 2 M HCl and stirred with DOWEX for 5 h. The 
compound was removed with 0.1 M HCl and the solvent evaporated under reduced 
pressure to give NODAHA (0.218 g, 0.464 mmol), as an oil, in a 96% yield. H (400 
MHz; D2O; DSS) 1.53 (2 H, m, CH2), 1.77 (2 H, m, CH2), 1.93 (2 H, m, CH2), 2.54 
(2 H, t, J = 7.6 Hz, CH2), 3.44-3.75 (14 H, m, CH2 and en), 3.94 (4 H, s, CH2CO2H). 
C (100.61 MHz; D2O; DSS) 23.47 (CH2), 23.78 (CH2), 25.29 (CH2), 33.71 (CH2), 
49.99 (en), 50.77 (en), 51.09 (en), 57.84 (CH2), 58.12 (CH2CO2H), 174.29 (CO2H) and 
178.93 (CH2CO2H). HRMS (ESI+) calculated for C16H30N3O6 (M+H)+ 360.21346. 
Found 360.21279. 
Potentiometric studies 
Carbonate-free 0.1 M KOH and 0.1 M HCl were prepared from Fisher Chemicals 
concentrates. Potentiometric titrations were performed in 0.1 M aqueous KCl under 
nitrogen atmosphere and the temperature was controlled to ± 0.1 °C with a circulating 
water bath. The p[H] (p[H] = -log[H+], concentration in molarity) was measured in each 
titration with a combined pH glass electrode (Metrohm) filled with 3 M KCl and the 
titrant addition was automated by use of a 702 SM titrino system (Metrohm). The 
electrode was calibrated in hydrogen ion concentration by titration of HCl with KOH in 
0.1 M electrolyte solution 57. A plot of meter reading versus p[H] allows the 
determination of the electrode standard potential (E°) and the slope factor (f). 
Continuous potentiometric titrations with HCl and KOH 0.1 M were conducted on 
aqueous solutions containing 5 mL of NODABA 1.55 mM, 5 mL of NODAHA 1.34 
mM, and 5 mL of NODAHep 3.08 mM in KCl 0.1 M, with 2 minutes waiting between 
successive points. The titrations of the metal complexes were performed with the same 
ligand solutions containing 1 equivalent of metal cation, with 2 minutes waiting time 
between 2 points. Experimental data were refined using the computer program 
Hyperquad 2008 58. All equilibrium constants are concentration quotients rather than 
activities and are defined as:  
 
ܭ௠௟௛ = [ܯ௠ܮ௟ܪ௛][ܯ]௠[ܮ]௟[ܪ]௛           (7) 
 
The ionic product of water at 298 K and 0.1 M ionic strength is pKw = 13.77 48. Fixed 
values were used for pKw, ligand acidity constants and total concentrations of metal, 
ligand and acid. All values and errors (one standard deviation) reported are at least the 
average of two consistent and independent experiments. 
1H NMR Titrations  
Stock solutions of NODAHep (11.24 mM), NODABA (10.92 mM), and NODAHA 
(10.15 mM) were prepared by dissolving the free chelator in D2O. The solution was 
titrated by addition of small aliquots of 0.1 M NaOD or DCl solutions. The final pH was 
corrected for the deuterium isotope effect using the equation pH = pD - 0.4 59. Plots of 
chemical shifts versus solution pH originated the acid-base titration curves. 
Critical micellar concentration determination 
Determination by fluorescence  
A 40.5 mM stock solution of [Mn(NODAHep)] was prepared in 0.1 M HEPES buffer 
pH 7.4. This concentration was close to the limit of solubility of the chelate. The 
estimation of the critical micellar concentration (cmc) was performed using ANS (8-
anilino-1-naphtalene sulfonic acid) as fluorescence probe 44. The solutions used in this 
study were prepared by dilution of the stock solution and each one contained 1x10-5 M 
ANS. The fluorescence was measured at 480 nm upon excitation at 350 nm at room 
temperature. The fluorescence measurements were recorded on a Bio-Tek® SynergyTM 
HT spectrofluorimeter using the software KC4TM. 
Relaxometric measurements 
A 41.34 mM stock solution of [Mn(NODAHep)] was prepared; by dilution it was 
possible to have a set of solutions in the concentration range 4.68 mM - 41.34 mM in 
0.5 M HEPES buffer pH 7.4, whose relaxivity was measured at 40 MHz and 298 K. 
1H NMRD studies  
Proton NMRD (nuclear magnetic relaxation dispersion) profiles were recorded on a 
Stelar SMARtracer Fast Field Cycling NMR relaxometer (0.01-10 MHz) and a Bruker 
WP80 NMR electromagnet adapted to variable field measurements and controlled by a 
SMARtracer PC-NMR console. The temperature was monitored by a VTC91 
temperature control unit and maintained by a gas flow. The temperature was determined 
by previous calibration with a Pt resistance temperature probe. The longitudinal 
relaxation rates (1/T1) were determined in water. The least-square fit of the 1H NMRD 
data were performed by using MicroMath Scientist version 2.0 (Salt Lake City, UT, 
USA). The concentrations and pH of solutions were as follows: [Mn(NODAHep)] 4.68 
mM; [Mn(NODABA)] 4.40 mM and [Mn(NODAHA)] 5.70 mM in 0.5 M HEPES 
buffer pH 7.4. The 1H NMRD profiles were obtained at 298, 310 and 323 K. HRMS 
(ESI+): [Mn(NODAHep)] – calculated for C17H32MnN3O4 (M+H)+ 397.1773. Found 
397.1761; [Mn(NODABA)] – calculated for C18H24MnN3O6 (M+H)+ 433.1046. Found 
433.1039; [Mn(NODAHA)] – calculated for C16H28MnN3O6 (M+H)+ 413.1359. Found 
413.1350. 
17O NMR studies 
The longitudinal and transverse 17O relaxation rates (1/T1,2) and the chemical shifts were 
measured in aqueous solutions of the various complexes in the temperature range 280-
350 K, on a Bruker Avance 500 (11.7 T, 67.8 MHz) spectrometer. The temperature was 
calculated according to previous calibration with ethylene glycol and methanol 60. An 
acidified water solution (HClO4, pH 3.3) was used as external reference. Transverse 
relaxation times (T2) were obtained by the Carr-Purcell-Meiboom-Gill spin-echo 
technique 61 and longitudinal relaxation times were measured by the inversion recovery 
sequence 62. The technique of the 17O NMR measurements on Gd3+ complexes has been 
described elsewhere 63. The samples were sealed in glass spheres fitted into 10 mm 
NMR tubes to avoid susceptibility corrections of the chemical shifts 64. To improve the 
sensitivity, 17O-enriched water (10% H217O, CortectNet) was added to the solutions to 
reach around 1% enrichment. The complex solutions were prepared in 0.5 M HEPES 
buffer at pH 7, and the concentrations were as follows: [Mn(NODAHep] = 4 mM; 
[Mn(NODAHA)] = 4.04 mM; [Mn(NODABA)] = 4.00 mM. The 17O NMR data have 
been treated according to the Solomon-Bloembergen-Morgan theory of paramagnetic 
relaxation 65 (see Supporting Information). The least-squares fit of the 17O NMR data 
were performed using Micromath Scientist version 2.0 (Salt Lake City, UT, USA). The 
reported errors correspond to two times the standard deviation. 
Interaction with HSA 
A Solution of [Mn(NODAHep)] (4.68 mM) and HSA (0.607 mM) was prepared in 0.5 
M HEPES buffer pH 7.4. The 1H NMRD profile was obtained at 298 K. 
pH stability range  
Solutions of [Mn(NODAHep)] (1 mM) were prepared in the pH range 1.72 - 9.25. The 
longitudinal relaxation rates were measured at 20 MHz and 298 K. The measurements 
were carried out in a BrukerMinispec MQ 20. 
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AAZTA = 6-amino-6-methylperhydro-1,4-diazepine triacetic acid 
ANS = 8-anilino-1-naphtalene sulfonic acid 
BOM = benzyloxymethyl 
cmc = critical micellar concentration 
CAs = contrast agents 
COSY = correlation spectroscopy 
d = duplet 
DCM = dichloromethane 
diph = diphenylcyclohexylphosphate 
DO2A = 1,4,7,10-tetraazacyclododecan-1,7-diacetic acid 
DO3A = 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid 
DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate 
DOTAM = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetamide 
DPDP = N,N’-dipyridoxylethylenediamine-N,N’-diacetate-5,5’-bis-(phosphate) 
DSS = sodium 2,2-dimethylsilapentane-5-sulfonate 
DTPA = diethylenetriaminepentaacetate 
EDTA = ethylenediamine tetraacetic acid 
en = ethylenic bridges 
ENOTA = dimeric triazacyclononane-based ligand 
ESI+ = positive electrospray ionization 
Fm = 9-fluorenylmethyl 
HEPES = 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HRMS = high-resolution mass spectrometry 
HSA = Human serum albumin 
m = multiplet 
MeCN = acetonitrile 
MeOH = methanol 
MRI = magnetic resonance imaging 
NMR = nuclear magnetic resonance 
NMRD = nuclear magnetic relaxation dispersion 
NO2AtBu = 1,4,7-triazacyclononane-1,4-diacetic acid tert-butyl ester 
NODABA = 1,4,7-triazacyclononane-1,4-diacetate-7-benzoic acid 
NODAHA = 1,4,7-triazacyclononane-1,4-diacetate-7-hexanoic acid 
NODAHep = 1,4,7-triazacyclononane-1,4-diacetate-7-heptanil 
NOTA = 1,4,7-triazacyclononane-1,4,7-triacetate 
NOTAC8 = 1,4,7-triazacyclononane-1,4-diacetic acid-7-octanoic acid- 
s = singlet 
SBM = Solomon-Bloembergen-Morgan 
t = triplet 
TFA = trifluoracetic acid 
TLC = thin layer chromatography 
TMS = tetramethylsilane 
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Supplementary Information. Figure S1. Determination of cmc of [Mn(NODAHep)] 
by paramagnetic relaxation enhancement measurements. Figure S2. Potentiometric 
titration curves of solutions containing NODAHA 1.34 mM with 0 or 1 equivalent of 
Mn2+ or Zn2+ in H2O, KCl 0.1 M, 298 K. Figure S3. Potentiometric titration curves of 
solutions containing NODABA 1.55 mM with 0 or 1 equivalent of Mn2+ or Zn2+ in 
H2O, KCl 0.1 M, 298 K. Figure S4. (Top) Temperature dependence of reduced 17O 
transverse relaxation rate of [Mn(NODAHA)]. (Bottom) 1H NMRD profiles of 
[Mn(NODAHA)] at 298, 310 and 323 K. Figure S5. (Top) Temperature dependence of 
reduced 17O transverse relaxation rate of [Mn(NODABA)]. (Bottom) 1H NMRD 
profiles of [Mn(NODABA)] at 298, 310 and 323 K. Figure S6. 1H NMRD profile of 
[Mn(NODAHep)] in the presence of HSA at 298 K. Equations used for the analysis of 
NMRD and 17O NMR data. 
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Scheme 1. Chemical structure of various chelators for Mn2+ discussed in this work. 
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Scheme 2. a: K2CO3 in MeCN; b: TFA in DCM; b’: 1 M NaOH in MeOH, ∆; c: 
MnCl2.4H2O in 0.5 M HEPES buffer, pH 7.4. 
  
Figure 1. Determination of cmc by fluorescence spectroscopy. The intersection of the 
linear regression curves of the fluorescence intensity of ANS at 480 nm as a function of 
the chelate concentration determines the cmc of NODAHep. 
 
 
 
Figure 2. Potentiometric titration curves of solutions containing NODAHep 3.08 mM 
with 0 or 1 equivalent of Mn2+ or Zn2+ in H2O, KCl 0.1 M, 298 K. 
 
 Figure 3. (Top) Temperature dependence of reduced 17O transverse relaxation rate of 
[Mn(NODAHep)]. (Bottom) 1H NMRD profiles of [Mn(NODAHep)] at 298 K (■), 
310 K (▲), and 323 K (●). 
 
 Figure 4. Stability of [Mn(NODAHep)] as a function of the pH: a) Paramagnetic 
relaxation enhancement measured at 1 mM, 20 MHz, and 298 K. b) Species distribution 
obtained in the same conditions from the stability constants (Table 1 and 2). 
 
Table 1. Protonation constants of various ligands at 298 K and in KCl = 0.1 M. 
 
 
 
 
 
 
 
 
 
 
 
 NODAHep NODAHA NODABA NOTA 
Log KH1 12.0(3) 11.1(2) 11.2(1) 11.41 
Log KH2 5.81(2) 6.00(5) 5.35(3) 5.74 
Log KH3 2.71(8) 4.53(2) 4.07(6) 3.16 
Log KH4  2.74(5) 3.04(9) 1.71 
Log KH5   2.0(1)  
Table 2. Stability constants, and pM values of NODAHep, NODAHA, NODABA, and 
NOTA complexes with Mn2+ and Zn2+ ions at 298 K, and in KCl 0.1 M. 
Log K NODAHep NODAHA NODABA NOTAa 
MnL 10.98(3) 10.15(5) 9.9(1) 14.9 
MnLH  4.95(5)   
MnLOH  9.65(5)   
ZnL 16.6(1) 15.65(7) 15.72(9) 18.6 
ZnLH  4.76(2) 4.25(8)  
ZnLH2   2.52(7)  
% free Mn2+ b 0.92 0.85 1.26 7.8x10-3 
pMnc 7.35 7.41 7.09 11.8 
a. From ref 48, 49. b. obtained at pH = 7.4 for [Mn] = [L] = 5 mM. c. pMn = - log [Mn]free 
for pH = 7.4, [Mn] = 10-6 M, [L] = 10-5 M. 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Best fit parameters obtained from the simultaneous analysis of 17O NMR and 
1H NMRD data. 
 MnNODAHep MnNODAHA MnNODABA Mn2ENOTAa Mn(H2O)6b 
kex298(106s-1) 2.7 (2) 2.7 (2) 1.3 (3) 5.5 2.1 
ΔH≠(kJ.mol-1) 23.4 (9) 23.5 (9) 10.9 (9) 20.5 32.9 
ΔS≠(J.mol-1.K-1) - 24 (2) - 24 (2) - 72 (4) - 28 + 5.7 
ER (kJ.mol-1) 25 (1) 24 (1) 27(1)  18  
τRO
298(ps) 84 (1) 80 (1) 121 (6) 85  
τv
298(ps) 60 (5) 69 (9) 60c 7.7 3.3 
Δ²(1018s-1) 70 (1) 70 (1) 70c  4.7 5.6 
A0/ћ(106rad.s-1) 30 (1) 30 (1) 33 (1) 32.7 33.3 
a From ref 15. b From ref 53. c These values have been fixed for the fitting (see text). 
